WO2009038012A1 - Composé hétérocyclique - Google Patents
Composé hétérocyclique Download PDFInfo
- Publication number
- WO2009038012A1 WO2009038012A1 PCT/JP2008/066400 JP2008066400W WO2009038012A1 WO 2009038012 A1 WO2009038012 A1 WO 2009038012A1 JP 2008066400 W JP2008066400 W JP 2008066400W WO 2009038012 A1 WO2009038012 A1 WO 2009038012A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heterocyclic compound
- pharmaceutically acceptable
- acceptable salt
- disease
- hyperalgesia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur un nouveau composé hétérocyclique représenté par la formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, ou sur une préparation pharmaceutique contenant le composé ou le sel pharmaceutiquement acceptable en tant qu'ingrédient actif, qui présente une activité agoniste puissante sur un récepteur NPFF2 et est par conséquent utile pour la prévention ou le traitement d'une maladie telle que la douleur, une hyperalgésie, un trouble de l'alimentation, l'obésité, le diabète ou une maladie cardiovasculaire.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007241502 | 2007-09-18 | ||
| JP2007-241502 | 2007-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009038012A1 true WO2009038012A1 (fr) | 2009-03-26 |
Family
ID=40467829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/066400 Ceased WO2009038012A1 (fr) | 2007-09-18 | 2008-09-11 | Composé hétérocyclique |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009038012A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130002991A (ko) * | 2010-02-08 | 2013-01-08 | 엠에스데 오쓰 베.베. | 8-메틸-1-페닐-이미다졸[1,5-a]피라진 화합물 |
| EP2567959A1 (fr) | 2011-09-12 | 2013-03-13 | Sanofi | Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs |
| WO2018152134A1 (fr) * | 2017-02-14 | 2018-08-23 | Research Triangle Institute | Modulateurs du récepteur ff de neuropeptide à base de proline |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62135473A (ja) * | 1985-12-06 | 1987-06-18 | Fujisawa Pharmaceut Co Ltd | イミダゾ−ル縮合複素環化合物 |
| WO2004058755A2 (fr) * | 2002-12-24 | 2004-07-15 | Biofocus Plc | Bibliotheques de composes |
| JP2007504220A (ja) * | 2003-09-03 | 2007-03-01 | ガラパゴス・エヌブイ | イミダゾ[1,5−a]ピリジン又はイミダゾ[1,5−a]ピペリジン誘導体および5HT2A受容体関連障害に対する薬剤の製造のためのその使用 |
| JP2007509060A (ja) * | 2003-10-15 | 2007-04-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
-
2008
- 2008-09-11 WO PCT/JP2008/066400 patent/WO2009038012A1/fr not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62135473A (ja) * | 1985-12-06 | 1987-06-18 | Fujisawa Pharmaceut Co Ltd | イミダゾ−ル縮合複素環化合物 |
| WO2004058755A2 (fr) * | 2002-12-24 | 2004-07-15 | Biofocus Plc | Bibliotheques de composes |
| JP2007504220A (ja) * | 2003-09-03 | 2007-03-01 | ガラパゴス・エヌブイ | イミダゾ[1,5−a]ピリジン又はイミダゾ[1,5−a]ピペリジン誘導体および5HT2A受容体関連障害に対する薬剤の製造のためのその使用 |
| JP2007509060A (ja) * | 2003-10-15 | 2007-04-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130002991A (ko) * | 2010-02-08 | 2013-01-08 | 엠에스데 오쓰 베.베. | 8-메틸-1-페닐-이미다졸[1,5-a]피라진 화합물 |
| KR101661383B1 (ko) | 2010-02-08 | 2016-09-29 | 머크 샤프 앤 도메 비.브이. | 8-메틸-1-페닐-이미다졸[1,5-a]피라진 화합물 |
| EP2567959A1 (fr) | 2011-09-12 | 2013-03-13 | Sanofi | Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs |
| WO2018152134A1 (fr) * | 2017-02-14 | 2018-08-23 | Research Triangle Institute | Modulateurs du récepteur ff de neuropeptide à base de proline |
| CN110546136A (zh) * | 2017-02-14 | 2019-12-06 | 研究三角协会 | 基于脯氨酸的神经肽ff受体调节剂 |
| EP3583090A1 (fr) | 2017-02-14 | 2019-12-25 | Research Triangle Institute, International | Modulateurs du récepteur ff de neuropeptide à base de proline |
| EP3583090A4 (fr) * | 2017-02-14 | 2020-12-30 | Research Triangle Institute, International | Modulateurs du récepteur ff de neuropeptide à base de proline |
| US11491136B2 (en) | 2017-02-14 | 2022-11-08 | Research Triangle Institute | Proline-based neuropeptide FF receptor modulators |
| CN110546136B (zh) * | 2017-02-14 | 2023-07-18 | 研究三角协会 | 基于脯氨酸的神经肽ff受体调节剂 |
| US11826350B2 (en) | 2017-02-14 | 2023-11-28 | Research Triangle Institute | Proline-based neuropeptide FF receptor modulators |
| US12390446B2 (en) | 2017-02-14 | 2025-08-19 | Research Triangle Institute | Proline-based neuropeptide FF receptor modulators |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010122980A8 (fr) | Nouvel agoniste du récepteur ss de l'hormone thyroïdienne | |
| WO2008136392A1 (fr) | Préparation pour une administration orale | |
| WO2009051119A1 (fr) | Composé de pyrimidylindoline | |
| MX2009011276A (es) | Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad. | |
| WO2007060140A3 (fr) | Inhibiteurs de diacylglycérol acyltransférase (dgat) | |
| WO2010026436A3 (fr) | Composés pharmaceutiques | |
| WO2009111700A3 (fr) | Oxadiazoanthracènes pour le traitement du diabète | |
| WO2005044192A3 (fr) | Composes triazole et utilisations associees | |
| ZA200706021B (en) | 1-thio-D-glucitol derivatives | |
| WO2007135527A3 (fr) | Composés de benzimidazolyle | |
| UA94455C2 (en) | Oxadiazolidinedione compound | |
| WO2009010416A3 (fr) | Inhibiteurs de 11b-hydroxystéroïde déshydrogenase | |
| ZA200706354B (en) | Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses | |
| WO2005075425A3 (fr) | Derives de bisaryluree | |
| WO2007106181A3 (fr) | Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques | |
| WO2006124447A3 (fr) | N-arylpyrrolidines substituees utilisees comme modulateurs selectifs du recepteur des androgenes | |
| WO2009004082A3 (fr) | Compositions pharmaceutiques anticonvulsives | |
| WO2004052370A3 (fr) | Utilisation de composes de la quinoline pour traiter des troubles lies au recepteur mch | |
| WO2008156094A1 (fr) | Dérivé de pyridazinone et inhibiteur de la pde le contenant comme ingrédient actif | |
| WO2007065808A3 (fr) | Agonistes du récepteur du neuropeptide-2 | |
| WO2010052144A3 (fr) | Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations | |
| WO2006020959A3 (fr) | Heterocycles benzo-condenses substitues | |
| WO2011045232A3 (fr) | Agonistes du récepteur du neuropeptide-2 (y-2r) | |
| WO2007105113A3 (fr) | Application des antagonistes du récepteur crf1 à l'élaboration d'un médicament destiné au traitement du syndrome métabolique et/ou de l'obésité et/ou d'une dyslipoprotéinémie | |
| WO2007120270A3 (fr) | Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08831339 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08831339 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |